Anthem Biosciences Ltd
ANTHEM • Health Care
ROCE
26.90%
FY24 Actual
D/E Ratio
0.05
Zero Debt
5Y Rev CAGR
24.2%
High Growth
Profit Margin
27.2%
5Y Average
| Metrics (Values in Cr) | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 1,140.45 | 1,280.24(+12.3%) | 1,195.79(-6.6%) | 1,483.07(+24.0%) | 1,930.28(+30.2%) | 2,180.72 |
| Operating Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Profit | — | — | — | — | — | — |
| Raw Profit | 407.88 | 410.3(+0.6%) | 348.29(-15.1%) | 640.79(+84.0%) | 830.62(+29.6%) | — |
| Operating Expenses | 77.54 | 33.82(-56.4%) | 24.75(-26.8%) | 3.23(-86.9%) | -29.89(-1025.4%) | 1,307.14 |
| Selling General And Administrative Expenses | 33.68 | 48.3(+43.4%) | 60.79(+25.9%) | 55.19(-9.2%) | 64.52(+16.9%) | — |
| Depreciation And Amortization | 62.4 | 57.76(-7.4%) | 63.7(+10.3%) | 81.82(+28.4%) | 89.37(+9.2%) | 110.65 |
| Profit Before Interest | 382.53 | 556.22(+45.4%) | 506.01(-9.0%) | 486.98(-3.8%) | 667.39(+37.0%) | 762.93 |
| Interest Expense | 16.97 | 10.09(-40.5%) | 8.72(-13.6%) | 9.66(+10.8%) | 10.53(+9.0%) | 7.71 |
| Profit Before Tax | 365.56 | 546.13(+49.4%) | 497.29(-8.9%) | 477.32(-4.0%) | 656.86(+37.6%) | 755.22 |
| Tax Expense | 94.27 | 140.6(+49.1%) | 112.11(-20.3%) | 110.01(-1.9%) | 205.61(+86.9%) | 239.03 |
| Net Income | 271.29 | 405.53(+49.5%) | 385.18(-5.0%) | 367.31(-4.6%) | 451.25(+22.9%) | 516.19 |
| Earnings Per Share | 4.95 | 7.229(+46.0%) | 6.752(-6.6%) | 6.504(-3.7%) | 8.071(+24.1%) | 9.233 |
| Dividends Per Share | 0 | 0 | 0 | 0 | 0 | 0 |
| Payout Ratio | 0 | 0 | 0 | 0 | 0 | 0 |